Magenta Therapeutics Reports Third Quarter Financial Results and Recent Program Highlights
– New clinical results from ongoing MGTA-117 Phase 1/2 clinical trial support earlier observations of target binding, target cell depletion, rapid drug clearance and a favorable tolerability... | November 3, 2022
United Kingdom United States Jill Bertotti Jason Gardner Magenta Therapeutics Inc Good Laboratory Practices
Source: marketscreener.com